AC Immune Reports Third Quarter 2025 Financial Results and Provides a Corporate Update

GlobeNewswire
2025.11.04 12:39
portai
I'm PortAI, I can summarize articles.

AC Immune Reports Third Quarter 2025 Financial Results and Provides a Corporate Update • Sharpened investment focus on high-value assets, including three Phase 2 active immunotherapy programs and small molecule programs targeting NLRP3, Tau and a-syn • Cash resources of CHF 108.5 million as of ...

Source: GlobeNewswire The copyright of this article belongs to the original author/organization.
The views expressed herein are solely those of the author and do not reflect the stance of the platform. The content is intended for investment reference purposes only and shall not be considered as investment advice. Please contact us if you have any questions or suggestions regarding the content services provided by the platform.
© 2025 Longbridge｜Disclaimer